Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” ...

A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...

ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including ...

The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...